| Assessment Status |
Rapid Review Complete |
| HTA ID |
26037 |
| Drug |
Datopotamab deruxtecan |
| Brand |
Datroway® |
| Indication |
Datopotamab deruxtecan as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. |
| Rapid review commissioned |
13/07/2026 |
| Rapid review completed |
21/08/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of datopotamab deruxtecan (Datroway®) compared with the current standard of care. |
